SSC
ENTA icon

Spruce Street Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Spruce Street Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9M Buy
1,088,731
+156,133
+17% +$2.1M 3.11% 11
2026
Q1 		$11.8M Buy
932,598
+542,911
+139% +$7.28M 2.83% 13
2025
Q4 		$6.15M Buy
+389,687
New +$4.95M 2.03% 20

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spruce Street Capital's ENTA Position: Q2 2026 in Review

Spruce Street Capital increased its Enanta Pharmaceuticals (ENTA) stake by 17% in Q2 2026, buying an estimated $2.1M and bringing the position to 1,088,731 shares worth $15.9M. The position accounts for 3.11% of the portfolio, ranked #11.

Spruce Street Capital first reported a position in ENTA in Q4 2025 and has held it in 3 quarters since. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Spruce Street Capital held 1,088,731 shares of Enanta Pharmaceuticals worth $15.9M as of Q2 2026.
  • Spruce Street Capital bought 156,133 Enanta Pharmaceuticals shares in Q2 2026, an estimated $2.1M.
  • Enanta Pharmaceuticals made up 3.11% of Spruce Street Capital's portfolio in Q2 2026, its #11 holding.
  • Spruce Street Capital first reported a position in Enanta Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.